Farley Cleghorn

2.5k total citations · 1 hit paper
34 papers, 1.7k citations indexed

About

Farley Cleghorn is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Farley Cleghorn has authored 34 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Virology and 15 papers in Immunology. Recurrent topics in Farley Cleghorn's work include HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (14 papers) and T-cell and Retrovirus Studies (12 papers). Farley Cleghorn is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS Research and Interventions (14 papers) and T-cell and Retrovirus Studies (12 papers). Farley Cleghorn collaborates with scholars based in United States, Trinidad and Tobago and Jamaica. Farley Cleghorn's co-authors include Chris Beyrer, Stefan Baral, Frangiscos Sifakis, William A. Blattner, Noreen Jack, Courtenay Bartholomew, Anne Sill, C Bartholomew, Robert J. Edwards and Robert C. Gallo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Farley Cleghorn

34 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Elevated Risk for HIV Infection among Men Who Have Sex with Men in Low- and Middle-Income Countries 2000–2006: A Systematic Review

2007 557 citations Stefan Baral, Frangiscos Sifakis et al. PLoS Medicine profile →

Peers

Countries citing papers authored by Farley Cleghorn

Since Specialization

Citations

This map shows the geographic impact of Farley Cleghorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farley Cleghorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farley Cleghorn more than expected).

Fields of papers citing papers by Farley Cleghorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farley Cleghorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farley Cleghorn. The network helps show where Farley Cleghorn may publish in the future.

Co-authorship network of co-authors of Farley Cleghorn

This figure shows the co-authorship network connecting the top 25 collaborators of Farley Cleghorn. A scholar is included among the top collaborators of Farley Cleghorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farley Cleghorn. Farley Cleghorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Strengthening primary health care in low- and middle-income countries: furthering structural changes in the post-pandemic era 2024 ·Frontiers in Public Health ·(unknown), (unknown), Farley Cleghorn, Carlos Ávila	12
2	Improving management of tuberculosis in people living with HIV in South Africa through integration of HIV and tuberculosis services: a proof of concept study 2018 ·BMC Health Services Research ·Irit Sinaï, Farley Cleghorn, (unknown)	12
3	Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries 2012 ·Current Opinion in HIV and AIDS ·Arindam Dutta, Andrea L. Wirtz, Stefan Baral, Chris Beyrer, Farley Cleghorn	66
4	HIV-1 Epidemic in the Caribbean Is Dominated by Subtype B 2009 ·PLoS ONE ·Yuka Nadai, Lindsay M. Eyzaguirre, Anne Sill, Farley Cleghorn, Claudine Nolte, Manhattan Charurat, (unknown), Noreen Jack, Courtenay Bartholomew, Jean W. Pape, Peter Figueroa, William A. Blattner, Jean K. Carr	22
5	Protocol for Nearly Full-Length Sequencing of HIV-1 RNA from Plasma 2008 ·PLoS ONE ·Yuka Nadai, Lindsay M. Eyzaguirre, Niel T. Constantine, Anne Sill, Farley Cleghorn, William A. Blattner, Jean K. Carr	48
6	Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120 2007 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Farley Cleghorn, Jean W. Pape, Mauro Schechter, Courtenay Bartholomew, Jorge Sánchez, Noreen Jack, Barbara Metch, Marianne Hansen, Mary Allen, Huyen Cao, David C. Montefiori, Georgia D. Tomaras, Sanjay Gurunathan, Donna J. Eastman, Regina Ferro do Lago, (unknown), Javier R. Lama, Dale N. Lawrence, Peter F. Wright	25
7	A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection 2007 ·International Journal of Infectious Diseases ·Hong Li, Fassil Ketema, Anne Sill, Kristen Kreisel, Farley Cleghorn, Niel T. Constantine	15
8	Tenofovir and Abacavir Combination Therapy: Lessons Learned from an Urban Clinic Population 2007 ·AIDS Patient Care and STDs ·Bruce L. Gilliam, Mohammad M. Sajadi, Anthony Amoroso, Charles E. Davis, Farley Cleghorn, Robert Redfield	9
9	Elevated Risk for HIV Infection among Men Who Have Sex with Men in Low- and Middle-Income Countries 2000–2006: A Systematic Review breakdown → 2007 ·PLoS Medicine ·Stefan Baral, Frangiscos Sifakis, Farley Cleghorn, Chris Beyrer	557
10	Improved Classification of Recent HIV-1 Infection by Employing a Two-Stage Sensitive/Less-Sensitive Test Strategy 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Niel T. Constantine, Anne Sill, Noreen Jack, Kristen Kreisel, Robert J. Edwards, (unknown), Harry Smith, Courtenay Bartholomew, Farley Cleghorn, William A. Blattner	38
11	Immunologic and Virologic Analyses of an Acutely HIV Type 1-Infected Patient with Extremely Rapid Disease Progression 2001 ·AIDS Research and Human Retroviruses ·James F. Demarest, Noreen Jack, Farley Cleghorn, Michael Greenberg, Trevor L. Hoffman, Janet Ottinger, Lori E. Fantry, Robert J. Edwards, Thomas R. OʼBrien, Kai Cao, (unknown), William A. Blattner, Courtenay Bartholomew, Kent J. Weinhold	18
12	Geographic diversity of adult t-cell leukemia/lymphoma in Brazil 1999 ·International Journal of Cancer ·Maria S. Pombo‐de‐Oliveira, Paula Loureiro, (unknown), (unknown), Davimar Miranda Maciel Borducchi, Sílvia Maia Farias de Carvalho, Helenemarie S. Barbosa, María Rios, Anne Sill, Farley Cleghorn, William A. Blattner, (unknown)	43
13	A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn 1999 ·International Journal of Cancer ·Paul H. Levine, Harvey Dosik, (unknown), Susanne Felton, (unknown), (unknown), (unknown), (unknown), (unknown), Stanley L. Lee, (unknown), (unknown), Elaine S. Jaffe, Constantine A. Axiotis, Farley Cleghorn, Amy R. Kahn, Seth L. Welles	15
14	Incidence of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in Jamaica and Trinidad 1998 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Elizabeth M. Maloney, Farley Cleghorn, (unknown), Pamela Rodgers‐Johnson, Beverly Cranston, Noreen Jack, William A. Blattner, Courtenay Bartholomew, Angela Manns	96
15	Direct and Indirect Estimates of HIV-1 Incidence in a High-Prevalence Population 1998 ·American Journal of Epidemiology ·Farley Cleghorn, Noreen Jack, Justin Murphy, Robert J. Edwards, (unknown), (unknown), Thomas R. OʼBrien, Michael Greenberg, Kent J. Weinhold, C Bartholomew, Ron Brookmeyer, William A. Blattner	22
16	Human T‐cell lymphotropic virus type I‐associated facial nerve palsy in trinidad and tobago 1997 ·Annals of Neurology ·Courtenay Bartholomew, Farley Cleghorn, Noreen Jack, Robert J. Edwards, William Blattner	17
17	HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression. 1996 ·Journal of Clinical Investigation ·Irena Štefanová, M. Wayne Saville, Christian Peters, Farley Cleghorn, Daniella M. Schwartz, David Venzon, Kent J. Weinhold, Noreen Jack, C Bartholomew, W. A. Blattner, Robert Yarchoan, Joseph B. Bolen, Ivan D. Horak	79
18	Effect of Human T-Lymphotropic Virus Type I Infection on Non-Hodgkin's Lymphoma Incidence 1995 ·JNCI Journal of the National Cancer Institute ·Farley Cleghorn, A Manns, Roni T. Falk, Patricia Hartge, B Hanchard, Noreen Jack, Edith M. Williams, ES Jaffe, F. White, C Bartholomew, W. A. Blattner	67
19	Comparison of HHV-6 antibody titers in West Africa and the Caribbean 1995 ·Annals of Epidemiology ·Farley Cleghorn, (unknown), Noreen Jack, Ernest Pate, J. A. A. Mingle, Paul H. Levine, Angela Manns	4
20	Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago 1993 ·The Lancet ·A Manns, Farley Cleghorn, Roni T. Falk, Patricia Hartge, Joseph Bénichou, William A. Blattner, Elaine S. Jaffe, B Hanchard, C Bartholomew	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact